Eyegate Pharmaceuticals, Inc. (EYEG) Earns Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) in a research note issued to investors on Thursday. They currently have a $6.00 price target on the specialty pharmaceutical company’s stock.
Shares of Eyegate Pharmaceuticals (NASDAQ EYEG) traded down $0.03 during mid-day trading on Thursday, hitting $1.12. 104,500 shares of the stock traded hands, compared to its average volume of 151,252. Eyegate Pharmaceuticals has a 1 year low of $0.90 and a 1 year high of $3.90.
COPYRIGHT VIOLATION WARNING: “Eyegate Pharmaceuticals, Inc. (EYEG) Earns Buy Rating from HC Wainwright” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/eyegate-pharmaceuticals-inc-eyeg-earns-buy-rating-from-hc-wainwright/1698625.html.
An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC purchased a new position in shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 345,524 shares of the specialty pharmaceutical company’s stock, valued at approximately $473,000. Sabby Management LLC owned 2.01% of Eyegate Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.05% of the company’s stock.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.